Expert Interviews

Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma
December 06, 2021

Nina Shah, MD, discusses breakthroughs in the treatment of multiple myeloma throughout the preceding year.

Major Breakthroughs in Treating Chronic Lymphocytic Leukemia
December 06, 2021

Susan M. O'Brien, MD, discusses breakthroughs in the treatment of chronic lymphocytic leukemia throughout the preceding year.

Second-Line Therapy for High-Risk Primary Myelofibrosis
December 06, 2021

Second-line treatment considerations for a 75-year-old man with high-risk primary myelofibrosis who was previously treated with ruxolitinib.

Second-Line Treatment Options for Myelofibrosis
December 06, 2021

Second-line therapies for myelofibrosis that are available or in the pipeline for use.

Patient Case 1: Discussion
December 03, 2021

The panel continues their conversation about the first patient case.

Patient Case 1: A 65-Year-Old Man With RCC
December 03, 2021

Toni Choueiri, MD, introduces the first patient case: a 65-year-old man with advanced-stage renal cell carcinoma.

Presentation: Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State
December 03, 2021

Drs. Gupta and Brown review a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.

Exciting Advances in the Therapeutic Space and Clinical Pearls for Treating Metastatic Prostate Cancer
December 02, 2021

Alicia Morgans, MD, MPH, lists several advances being made while treating metastatic prostate cancer and offers advice to clinicians who don’t see patients with the disease very often.

Sequencing Strategies for Metastatic Castration-Resistant Prostate Cancer Therapy
December 02, 2021

An expert examines sequencing strategies for the treatment of metastatic prostate cancer.

Updated Safety Data and Treatment Selection in nmCRPC
December 02, 2021

Dr Aaron Berger shares updated safety data on next-generation androgen receptor inhibitors and impact of safety profile on treatment selection in nmCRPC.